Step aside Wall Street, small pharma CEO pay reaches for the sky

An examination of biopharma company CEO salaries shows that many are paid like a hybrid of entrepreneurs and blue chip company CEOs, giving these executives the best of both worlds.

They may not be running too big to fail firms, but the CEOs of many small biopharmaceutical companies are being paid like they are unquestionably indispensable, In fact, many are making more than Wall Street’s chief executives and the CEOs of their much larger pharmaceutical peers.

• Paul Hodgson, Fortune

@pghwrites

Read the rest here.

Target Chief's $47 Million Retirement and America's 401(k) Gap

The gap in the U.S. workplace between the highest and lowest paid has been growing for years. Far less noticed has been the growing gulf in retirement pay.

While the very top often continue to receive executive pensions as well as other benefits, most workers are left only with their 401(k) plans.

By Carol Hymowitz and Margaret Collins, Bloomberg 

Read the rest here.

Pay package swells for Jabil CEO Mark Mondello

Jabil Circuit Inc.'s board of directors boosted compensation for CEO Mark Mondello in an effort similar to keeping up with the Jones'.

Mondello got a 40 percent boost in pay in fiscal 2014, ended Aug. 31, and received total compensation of $6.5 million for the year, according to a proxy filed with theU.S. Securities and Exchange Commission. He received $4.7 million in total compensation in the previous year.

Margie Manning, Print Editor, Tampa Bay Business Journal

Email  |  Facebook  |  Twitter  | Google+

Read the rest of the article here.